"Glucosylceramidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycosidase that hydrolyzes a glucosylceramide to yield free ceramide plus glucose. Deficiency of this enzyme leads to abnormally high concentrations of glucosylceramide in the brain in GAUCHER DISEASE. EC 3.2.1.45.
MeSH Number(s)
D08.811.277.450.420.475.400
Concept/Terms
Glucosylceramidase- Glucosylceramidase
- Glucocerebrosidase
- Glucocerebroside beta-Glucosidase
- Glucocerebroside beta Glucosidase
- beta-Glucosidase, Glucocerebroside
- Glucosyl Ceramidase
- Ceramidase, Glucosyl
- Glucosylceramide beta-Glucosidase
- Glucosylceramide beta Glucosidase
- beta-Glucosidase, Glucosylceramide
- Glucosylsphingosine Glucosyl Hydrolase
- Glucosyl Hydrolase, Glucosylsphingosine
- Hydrolase, Glucosylsphingosine Glucosyl
- Acid beta-Glucosidase
- Acid beta Glucosidase
- beta-Glucosidase, Acid
- beta-Glucocerebrosidase
- beta Glucocerebrosidase
Below are MeSH descriptors whose meaning is more general than "Glucosylceramidase".
Below are MeSH descriptors whose meaning is more specific than "Glucosylceramidase".
This graph shows the total number of publications written about "Glucosylceramidase" by people in Harvard Catalyst Profiles by year, and whether "Glucosylceramidase" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 |
1995 | 1 | 1 | 2 |
1996 | 1 | 0 | 1 |
1998 | 0 | 1 | 1 |
2002 | 2 | 0 | 2 |
2004 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2008 | 2 | 0 | 2 |
2009 | 3 | 1 | 4 |
2010 | 4 | 1 | 5 |
2011 | 2 | 0 | 2 |
2012 | 3 | 1 | 4 |
2013 | 2 | 0 | 2 |
2014 | 2 | 4 | 6 |
2015 | 4 | 1 | 5 |
2016 | 5 | 1 | 6 |
2017 | 1 | 0 | 1 |
2018 | 3 | 2 | 5 |
2019 | 3 | 2 | 5 |
2020 | 5 | 5 | 10 |
2021 | 5 | 5 | 10 |
2022 | 2 | 3 | 5 |
Below are the most recent publications written about "Glucosylceramidase" by people in Profiles.
-
Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism. Mov Disord. 2022 11; 37(11):2217-2225.
-
What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs. Neurology. 2022 08 16; 99(7 Suppl 1):34-41.
-
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Mov Disord. 2022 05; 37(5):1016-1027.
-
Assessment of Glucocerebrosidase Enzyme Activity in Parkinson Disease Using Multiple Approaches. Mov Disord. 2022 03; 37(3):655-656.
-
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis. 2022; 12(2):557-570.
-
Glycosphingolipid metabolism and its role in ageing and Parkinson's disease. Glycoconj J. 2022 02; 39(1):39-53.
-
Wild-type GBA1 increases the a-synuclein tetramer-monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice. Proc Natl Acad Sci U S A. 2021 08 03; 118(31).
-
Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nat Genet. 2021 06; 53(6):787-793.
-
Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression. JAMA Netw Open. 2021 04 01; 4(4):e215845.
-
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. Am J Hematol. 2021 05 01; 96(5):545-551.